Author

A. Bardia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

B. S. Wittner· 2 shared D. A. Haber· 2 shared D. T. Ting· 2 shared E. Antmen· 2 shared S. Maheswaran· 2 shared , I. Makhoul· 1 shared A. Bild· 1 shared A. Deshpande· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

B. S. Wittner

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product

A. Mishra, S.-B. Huang, T. Dubash, R. Burr, B. S. Wittner, Q. E. Cunneely, V. R. Putaturo, A. Deshpande, E. Antmen, K. A. Gopinathan, K. Otani, Y. Miyazawa, J. E. Kwak, S. Y. Guay, J. Kelly, , M. Toner

This study uses high-throughput microfluidic technology to enrich CTCs from large blood volumes, enabling detailed molecular and morphological analysis of tumor cells in metastatic cancer patients.

bioRxiv · Mar 13, 2024 · PreprintBioengineering

CDKN1B (p27kip1) enhances drug tolerant persister CTCs by restricting polyploidy following mitotic inhibitors.

E. Horwitz, T. D. Dubash, A. Szabolcs, B. S. Wittner, J. Kreuzer, R. Morris, A. Bardia, B. Chirn, D. Wiley, D. Che, H. C. Russel, X. I. H. Lopez, D. B. Fox, E. Antmen, D. T. Ting, , D. A. Haber

This study identifies CDKN1B as a regulator of drug-tolerant persister CTCs by preventing polyploidy after mitotic inhibitor treatment in breast cancer.

bioRxiv · Feb 20, 2024 · PreprintCancer Biology

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitors

J. I. Griffiths, J. Chen, P. A. Cosgrove, A. O'Dea, P. Sharma, C. Ma, M. Trivedi, K. Kalinsky, K. B. Wisinski, R. O'Regan, , I. Makhoul, L. M. Spring, A. Bardia, F. R. Adler, A. L. Cohen, , A. Bild

This study examines how breast cancer tumors evolve during early stage treatment with combination CDK and endocrine inhibitors, finding convergent resistance pathways and increased subclonal diversity with combination therapy.

bioRxiv · Jan 19, 2021 · PreprintCancer Biology